Perspective Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $264.23M
- P/E (TTM)
- –
- Dividend yield
- –
About Perspective Therapeutics
Pharmaceutical Preparations, SIC 2834
Perspective Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapies and alpha-particle therapeutic drug candidates to treat serious diseases. Its pipeline of investigational drug product candidates includes PSV359, VMT-α-NET, and VMT01, which are undergoing research and clinical evaluation. The company conducts research, clinical development, and finishing operations for its therapeutic assets, supported by subsidiaries including Viewpoint Molecular Targeting, Inc. and Isoray Medical, Inc. Its intended end users and customers encompass patients participating in clinical trials, physicians, healthcare payors, and major treatment centers.
The company maintains its principal executive offices in Seattle, Washington. Perspective Therapeutics conducts its operations domestically within the United States, utilizing facilities in Seattle as well as Coralville, Iowa. Its physical infrastructure includes office space and specialized finishing facilities intended to supply drug candidates to treatment centers across the country.
Summary of the business section of Perspective Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Perspective Therapeutics, Inc.
- Headquarters
- Seattle, WA
- Address
- 2401 Elliott Avenue, Suite 320 98121
- Phone
- (206) 676-0900
- Website
- perspectivetherapeutics.com
- Employees
- 166, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, San Francisco, CA, USA
Stock & identifiers
- Ticker
- CATX
- Exchange
- NYSE
- Shares outstanding
- 114M, Aug 5, 2026
- Public float
- $212.87M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jun 17, 2024; 1-for-10 reverse, Jun 14, 2024
- SEC CIK
- 728387
- CUSIP
- 46489V302
- ISIN
- US46489V3024
- LEI
- 5493005LRKM6BCABC605
- EIN
- 41-1458152
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Johan M. Spoor | Chief Executive Officer, Director | 87,683 |
| Jonathan Robert Hunt | Chief Accounting Officer | 59,800 |
| Markus Puhlmann | Chief Medical Officer | 1,375,425 |
| Joel Sendek | Chief Financial Officer | – |
| Juan Graham | Chief Financial Officer | 35,354 |
| Maria E. Martinez | Director | – |
| Lori A. Woods | Director | 188,267 |
| Frank Morich | Director | – |
| Robert F. Williamson III | Director | 118,846 |
| Heidi Henson | Director | 25,975 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Johan Thijs Spoor | $2.40M | $2.21M | $1.76M | $110 | – |
| FY2024 Johan Thijs Spoor | $5.38M | $2.19M | $1.77M | $128 | – |
| FY2023 Johan Thijs Spoor | $1.46M | $1.82M | $1.04M | $160 | – |
| FY2023 Lori AWoods | $671.73K | $776.66K | $1.04M | $160 | – |
| FY2022 Lori AWoods | $550.59K | $481.04K | $330.89K | $31 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 12, 2026, we employed 166 individuals, of which 163 were full-time employees and three were part-time employees.”
Corporate history
Events identified from SEC filings